| Symbol | ATYR |
|---|---|
| Name | ATYR PHARMA INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | 10240 SORRENTO VALLEY ROAD, SAN DIEGO, CA 92121 |
| Telephone | 8587318389 |
| Fax | — |
| — | |
| Website | https://www.atyrpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001339970 |
| Description | aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. Its focus is on the extracellular functionality and signaling pathways of tRNA synthetases. Its lead clinical product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. It is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung diseases (ILDs), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. Additional info from NASDAQ: |
New Form DEF 14A - aTYR PHARMA INC <b>Filed:</b> 2026-09-11 <b>AccNo:</b> 0001339970-26-000061 <b>Size:</b> 1 MB
Read moreaTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
Read moreNew Form PRE 14A - aTYR PHARMA INC <b>Filed:</b> 2026-08-31 <b>AccNo:</b> 0001339970-26-000058 <b>Size:</b> 1 MB
Read moreaTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD
Read moreNew Form S-8 - aTYR PHARMA INC <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0001339970-26-000055 <b>Size:</b> 336 KB
Read more(19% Negative) ATYR PHARMA INC (ATYR) Announces Clinical Trial Timeline Adjustment
Read moreNew Form SCHEDULE 13G/A - aTYR PHARMA INC <b>Filed:</b> 2026-07-27 <b>AccNo:</b> 0002012383-26-002254 <b>Size:</b> 10 KB
Read moreaTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
Read moreNew Form SCHEDULE 13G/A - aTYR PHARMA INC <b>Filed:</b> 2026-07-08 <b>AccNo:</b> 0001623632-26-000980 <b>Size:</b> 46 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05892614 | Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Pati… | Phase2 | Interstitial Lung Disease | Recruiting | 2023-10-26 | 2026-04-01 | ClinicalTrials.gov |
| NCT05415137 | Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarco… | Phase3 | Pulmonary Sarcoidosis | Completed | 2022-09-15 | 2025-07-14 | ClinicalTrials.gov |
| NCT04412668 | Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Particip… | Phase2 | SARS-CoV-2 (COVID-19) Severe Pneumonia | Completed | 2020-06-04 | 2020-10-23 | ClinicalTrials.gov |
| NCT03824392 | Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis | Phase1 | Pulmonary Sarcoidosis | Completed | 2019-01-29 | 2021-06-29 | ClinicalTrials.gov |
| NCT02836418 | Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity o… | Phase1 | Facioscapulohumeral Muscular Dystrophy | Completed | 2016-07-13 | 2017-04-18 | ClinicalTrials.gov |
| NCT02603562 | Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early … | Phase1 | Facioscapulohumeral Muscular Dystrophy (FSHD) | Completed | 2016-03-30 | 2016-12-12 | ClinicalTrials.gov |
| NCT02579239 | Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb G… | Phase1 | Limb-Girdle Muscular Dystrophies | Completed | 2015-11-30 | 2016-10-05 | ClinicalTrials.gov |
| NCT02531217 | Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Partic… | Phase1 | Facioscapulohumeral Muscular Dystrophy | Completed | 2015-08-13 | 2016-05-26 | ClinicalTrials.gov |
| NCT02239224 | Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in … | Phase1 | Facioscapulohumeral Muscular Dystrophy (FSHD) | Completed | 2014-09-04 | 2015-12-14 | ClinicalTrials.gov |
| NCT01437345 | A Multicenter Collaborative Study on the Clinical Features, Expression Profilin… | — | Facioscapulohumeral Muscular Dystrophy | Completed | 2012-07-01 | 2017-08-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE3 | Pulmonary Sarcoidosis | COMPLETED | NCT05415137 |
| Efzofitimod 5 mg/kg | Other | Phase PHASE3 | Pulmonary Sarcoidosis | COMPLETED | NCT05415137 |
| Efzofitimod 3 mg/kg | Other | Phase PHASE3 | Pulmonary Sarcoidosis | COMPLETED | NCT05415137 |
| ATYR1940 | Other | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy (FSHD) | COMPLETED | NCT02239224 |
| Placebo | Other | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy (FSHD) | COMPLETED | NCT02239224 |
| Efzofitimod 5.0 mg/kg or Placebo | Other | Phase PHASE1 | Pulmonary Sarcoidosis | COMPLETED | NCT03824392 |
| Efzofitimod 3.0 mg/kg or Placebo | Other | Phase PHASE1 | Pulmonary Sarcoidosis | COMPLETED | NCT03824392 |
| Efzofitimod 1.0 mg/kg or Placebo | Other | Phase PHASE1 | Pulmonary Sarcoidosis | COMPLETED | NCT03824392 |
| Placebo | Other | Phase PHASE2 | SARS-CoV-2 (COVID-19) Severe Pneumonia | COMPLETED | NCT04412668 |
| Efzofitimod 3 mg/kg | Other | Phase PHASE2 | SARS-CoV-2 (COVID-19) Severe Pneumonia | COMPLETED | NCT04412668 |
| Efzofitimod 1 mg/kg | Other | Phase PHASE2 | SARS-CoV-2 (COVID-19) Severe Pneumonia | COMPLETED | NCT04412668 |
| ATYR1940 | Other | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy | COMPLETED | NCT02531217 |
| ATYR1940 | Other | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy (FSHD) | COMPLETED | NCT02603562 |
| Placebo | Other | Phase PHASE1 | Limb-Girdle Muscular Dystrophies | COMPLETED | NCT02579239 |
| ATYR1940 | Other | Phase PHASE1 | Limb-Girdle Muscular Dystrophies | COMPLETED | NCT02579239 |
| ATYR1940 | Other | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy | COMPLETED | NCT02836418 |
| Placebo | Other | Phase PHASE2 | Interstitial Lung Disease | RECRUITING | NCT05892614 |
| efzofitimod 270 mg | Other | Phase PHASE2 | Interstitial Lung Disease | RECRUITING | NCT05892614 |
| efzofitimod 450 mg | Other | Phase PHASE2 | Interstitial Lung Disease | RECRUITING | NCT05892614 |
| Placebo | Other | Phase PHASE3 | Pulmonary Sarcoidosis | ACTIVE_NOT_RECRUITING | NCT05415137 |
| Efzofitimod 5 mg/kg | Other | Phase PHASE3 | Pulmonary Sarcoidosis | ACTIVE_NOT_RECRUITING | NCT05415137 |
| Efzofitimod 3 mg/kg | Other | Phase PHASE3 | Pulmonary Sarcoidosis | ACTIVE_NOT_RECRUITING | NCT05415137 |
| efzofitimod 270 mg | DRUG | Phase PHASE2 | Interstitial Lung Disease | RECRUITING | NCT05892614 |
| efzofitimod 450 mg | DRUG | Phase PHASE2 | Interstitial Lung Disease | RECRUITING | NCT05892614 |
| Efzofitimod 5 mg/kg | DRUG | Phase PHASE3 | Pulmonary Sarcoidosis | ACTIVE_NOT_RECRUITING | NCT05415137 |
| Efzofitimod 3 mg/kg | DRUG | Phase PHASE3 | Pulmonary Sarcoidosis | ACTIVE_NOT_RECRUITING | NCT05415137 |
| Efzofitimod 1 mg/kg | DRUG | Phase PHASE2 | SARS-CoV-2 (COVID-19) Severe Pneumonia | COMPLETED | NCT04412668 |
| Efzofitimod 5.0 mg/kg or Placebo | BIOLOGICAL | Phase PHASE1 | Pulmonary Sarcoidosis | COMPLETED | NCT03824392 |
| Efzofitimod 3.0 mg/kg or Placebo | BIOLOGICAL | Phase PHASE1 | Pulmonary Sarcoidosis | COMPLETED | NCT03824392 |
| Efzofitimod 1.0 mg/kg or Placebo | BIOLOGICAL | Phase PHASE1 | Pulmonary Sarcoidosis | COMPLETED | NCT03824392 |
| ATYR1940 | DRUG | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy | COMPLETED | NCT02836418 |
| Placebo | DRUG | Phase PHASE2 | Interstitial Lung Disease | RECRUITING | NCT05892614 |